{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:12:20Z","timestamp":1770149540829,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ministry of Science and ICT, Republic of Korea","award":["No. 50547-2020"],"award-info":[{"award-number":["No. 50547-2020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12149-021-01607-6","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T14:02:22Z","timestamp":1617458542000},"page":"639-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of 225Ac-DOTA-rituximab using 64Cu-DOTA-rituximab"],"prefix":"10.1007","volume":"35","author":[{"given":"Chul-Hee","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-1659","authenticated-orcid":false,"given":"Ilhan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Keun","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyo Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanghyon","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Moo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,3]]},"reference":[{"issue":"Suppl 4","key":"1607_CR1","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1080\/10428190310001616944","volume":"44","author":"A Hagenbeek","year":"2003","unstructured":"Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma. 2003;44(Suppl 4):S37-47.","journal-title":"Leuk Lymphoma"},{"key":"1607_CR2","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","volume":"96","author":"MS Kaminski","year":"2000","unstructured":"Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259\u201366.","journal-title":"Blood"},{"key":"1607_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441\u20139.","journal-title":"N Engl J Med"},{"key":"1607_CR4","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00259-005-1770-7","volume":"32","author":"M Bienert","year":"2005","unstructured":"Bienert M, Reisinger I, Srock S, et al. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin\u2019s lymphoma: initial experience. Eur J Nucl Med Mol Imaging. 2005;32:1225\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1607_CR5","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1200\/JCO.2005.05.3470","volume":"24","author":"MF Leahy","year":"2006","unstructured":"Leahy MF, Seymour JF, Hicks RJ, et al. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2006;24:4418\u201325.","journal-title":"J Clin Oncol"},{"key":"1607_CR6","doi-asserted-by":"publisher","first-page":"966","DOI":"10.2174\/138161209787582020","volume":"15","author":"JH Turner","year":"2009","unstructured":"Turner JH. Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience. Curr Pharm Des. 2009;15:966\u201382.","journal-title":"Curr Pharm Des"},{"key":"1607_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00280-013-2087-z","volume":"71","author":"HJ Kang","year":"2013","unstructured":"Kang HJ, Lee SS, Byun BH, et al. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2013;71:945\u201353.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1607_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13139-013-0229-1","volume":"47","author":"GW Kang","year":"2013","unstructured":"Kang GW, Kang HJ, Shin DY, et al. Radioimmunotherapy with (131)i-rituximab in a patient with diffuse large B-cell lymphoma relapsed after treatment with (90)y-ibritumomab tiuxetan. Nucl Med Mol Imaging. 2013;47:281\u20134.","journal-title":"Nucl Med Mol Imaging"},{"key":"1607_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1743-7563.2011.01393.x","volume":"7","author":"HJ Kang","year":"2011","unstructured":"Kang HJ, Lee SS, Kim KM, et al. Radioimmunotherapy with (131)I-rituximab for patients with relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma (NHL). Asia Pac J Clin Oncol. 2011;7:136\u201345.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1607_CR10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s12149-019-01401-5","volume":"33","author":"I Lee","year":"2019","unstructured":"Lee I, Byun BH, Lim I, et al. Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma. Ann Nucl Med. 2019;33:881\u201390.","journal-title":"Ann Nucl Med"},{"key":"1607_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000346436","volume":"130","author":"I Lim","year":"2013","unstructured":"Lim I, Park JY, Kang HJ, et al. Prognostic significance of pretreatment 18F-FDG PET\/CT in patients with relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma treated by radioimmunotherapy using 131I-rituximab. Acta Haematol. 2013;130:74\u201382.","journal-title":"Acta Haematol"},{"key":"1607_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00280-016-3140-5","volume":"78","author":"DY Shin","year":"2016","unstructured":"Shin DY, Byun BH, Kim KM, et al. Radioimmunotherapy with (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2016;78:825\u201331.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1607_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2217\/imt.14.16","volume":"6","author":"C Seidl","year":"2014","unstructured":"Seidl C. Radioimmunotherapy with \u03b1-particle-emitting radionuclides. Immunotherapy. 2014;6:431\u201358.","journal-title":"Immunotherapy"},{"key":"1607_CR14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s002590050306","volume":"25","author":"MR McDevitt","year":"1998","unstructured":"McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25:1341\u201351.","journal-title":"Eur J Nucl Med"},{"key":"1607_CR15","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s00259-011-2023-6","volume":"39","author":"M Essler","year":"2012","unstructured":"Essler M, G\u00e4rtner FC, Neff F, et al. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging. 2012;39:602\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1607_CR16","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134.","journal-title":"J Nucl Med"},{"key":"1607_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros G, Roeske JC, McDevitt MR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311\u201328.","journal-title":"J Nucl Med."},{"key":"1607_CR18","first-page":"5084","volume":"63","author":"PE Borchardt","year":"2003","unstructured":"Borchardt PE, Yuan RR, Miederer M, et al. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003;63:5084\u201390.","journal-title":"Cancer Res"},{"key":"1607_CR19","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.2967\/jnumed.115.171371","volume":"57","author":"K Behling","year":"2016","unstructured":"Behling K, Maguire WF, L\u00f3pez Puebla JC, et al. Vascular targeted radioimmunotherapy for the treatment of glioblastoma. J Nucl Med. 2016;57:1576\u201382.","journal-title":"J Nucl Med"},{"key":"1607_CR20","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.apradiso.2012.07.014","volume":"70","author":"S Pomm\u00e9","year":"2012","unstructured":"Pomm\u00e9 S, Marouli M, Suliman G, et al. Measurement of the 225Ac half-life. Appl Radiat Isot. 2012;70:2608\u201314.","journal-title":"Appl Radiat Isot"},{"key":"1607_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435\u201345.","journal-title":"Blood"},{"key":"1607_CR22","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.apradiso.2009.02.060","volume":"67","author":"JY Kim","year":"2009","unstructured":"Kim JY, Park H, Lee JC, et al. Simple Cu-64 production and its application of Cu-64 ATSM. Appl Radiat Isot. 2009;67:1190\u20134.","journal-title":"Appl Radiat Isot"},{"key":"1607_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","volume":"72","author":"T Lindmo","year":"1984","unstructured":"Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77\u201389.","journal-title":"J Immunol Methods"},{"key":"1607_CR24","unstructured":"Snyder WS (1975) \"S\" absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet no. 11"},{"key":"1607_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11307-011-0537-8","volume":"14","author":"A Natarajan","year":"2012","unstructured":"Natarajan A, Gowrishankar G, Nielsen CH, et al. Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. Mol Imaging Biol. 2012;14:608\u201316.","journal-title":"Mol Imaging Biol"},{"key":"1607_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2967\/jnumed.118.210294","volume":"60","author":"SK Woo","year":"2019","unstructured":"Woo SK, Jang SJ, Seo MJ, et al. Development of 64Cu-NOTA-trastuzumab for HER2 targeting: a radiopharmaceutical with improved pharmacokinetics for human studies. J Nucl Med. 2019;60:26\u201333.","journal-title":"J Nucl Med"},{"key":"1607_CR27","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1182\/blood-2007-01-066803","volume":"110","author":"J Dahle","year":"2007","unstructured":"Dahle J, Borrebaek J, Jonasdottir TJ, et al. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood. 2007;110:2049\u201356.","journal-title":"Blood"},{"key":"1607_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.nucmedbio.2005.12.004","volume":"33","author":"J Dahle","year":"2006","unstructured":"Dahle J, Borrebaek J, Melhus KB, et al. Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. Nucl Med Biol. 2006;33:271\u20139.","journal-title":"Nucl Med Biol"},{"key":"1607_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ijrobp.2008.05.029","volume":"72","author":"J Dahle","year":"2008","unstructured":"Dahle J, Bruland OS, Larsen RH. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation. Int J Radiat Oncol Biol Phys. 2008;72:186\u201392.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1607_CR30","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u201333.","journal-title":"J Clin Oncol"},{"key":"1607_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11307-014-0783-7","volume":"17","author":"SY Huang","year":"2015","unstructured":"Huang SY, Bolch WE, Lee C, et al. Patient-specific dosimetry using pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) dynamic PET\/CT imaging before [131I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015;17:284\u201394.","journal-title":"Mol Imaging Biol"},{"key":"1607_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00259-017-3817-y","volume":"45","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Schmidt K, Afshar-Oromieh A, et al. Targeted alpha therapy of mCRPC: dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45:31\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1607_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/138161207779313768","volume":"13","author":"TJ Wadas","year":"2007","unstructured":"Wadas TJ, Wong EH, Weisman GR, et al. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des. 2007;13:3\u201316.","journal-title":"Curr Pharm Des"},{"key":"1607_CR34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.1064126","volume":"294","author":"MR McDevitt","year":"2001","unstructured":"McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537\u201340.","journal-title":"Science"},{"key":"1607_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/j.semnuclmed.2014.03.007","volume":"44","author":"G Sgouros","year":"2014","unstructured":"Sgouros G, Hobbs RF. Dosimetry for radiopharmaceutical therapy. Semin Nucl Med. 2014;44:172\u20138.","journal-title":"Semin Nucl Med"},{"key":"1607_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00259-005-1803-2","volume":"32","author":"O Couturier","year":"2005","unstructured":"Couturier O, Supiot S, Degraef-Mougin M, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging. 2005;32:601\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1607_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.apradiso.2019.01.020","volume":"146","author":"E Azor\u00edn-Vega","year":"2019","unstructured":"Azor\u00edn-Vega E, Rojas-Calder\u00f3n E, Ferro-Flores G, et al. Assessment of the radiation absorbed dose produced by 177Lu-iPSMA, 225Ac-iPSMA and 223RaCl2 to prostate cancer cell nuclei in a bone microenvironment model. Appl Radiat Isot. 2019;146:66\u201371.","journal-title":"Appl Radiat Isot"},{"issue":"3","key":"1607_CR38","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1088\/0031-9155\/56\/3\/012","volume":"56","author":"J Schwartz","year":"2011","unstructured":"Schwartz J, Jaggi J, O\u2019Donoghue J, et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011;56(3):721\u201333.","journal-title":"Phys Med Biol"},{"key":"1607_CR39","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1349-7006.2010.01480.x","volume":"101","author":"P Paudyal","year":"2010","unstructured":"Paudyal P, Paudyal B, Hanaoka H, et al. Imaging and biodistribution of Her2\/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. Cancer Sci. 2010;101:1045\u201350.","journal-title":"Cancer Sci"},{"key":"1607_CR40","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.0c00171","author":"L Li","year":"2020","unstructured":"Li L, Rousseau J, Jaraquemada-Pel\u00e1ez MG, et al. 225Ac-H4py4pa for targeted alpha therapy. Bioconjug Chem. 2020. https:\/\/doi.org\/10.1021\/acs.bioconjchem.0c00171.","journal-title":"Bioconjug Chem"},{"key":"1607_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.119.233122","volume":"61","author":"T Watabe","year":"2020","unstructured":"Watabe T, Liu Y, Kaneda-Nakashima K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models. J Nucl Med. 2020;61:563\u20139.","journal-title":"J Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01607-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-021-01607-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01607-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T13:57:43Z","timestamp":1619531863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-021-01607-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,3]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1607"],"URL":"https:\/\/doi.org\/10.1007\/s12149-021-01607-6","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,3]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}